Herpes Simplex -Epidemiology Forecast to 2028

DelveInsights Herpes Simplex Virus (HSV) Infections- Epidemiology Forecast to 2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of HSV infections in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
Geography Covered
The United States
EU5 (Germany, France, Italy, Spain and the United Kingdom)
Japan
Study Period: 2016-2028
HSV infections Epidemiology
The HSV Infections epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for HSV Infections are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
HSV Infections Epidemiology Segmentation
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [total prevalent cases, prevalent cases by types (Genital Herpes and Herpes Labialis), diagnosed prevalence] of HSV infections in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2028.
The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
According to DelveInsight, total prevalent population of HSV infections in 7 major markets was estimated to be about 228,552,199 in 2016.
Report Scope
The report covers detailed overview of HSV infections explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
The report provides the insight about the historical and forecasted patient pool of HSV infections in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
The Report assesses the disease risk and burden and highlights the unmet needs of the disease
The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
The report provides the segmentation of the disease epidemiology by types and diagnosed prevalent cases of HSV infections in 7MM

Key strengths
10 Year Forecast of HSV infections epidemiology
7MM Coverage
Total Prevalent Cases of HSV infections
Prevalent Cases according to segmentation: HSV infections by clinical types (Genital Herpes and Herpes Labialis) in 7MM
Diagnosed cases of HSV infections
Key assessments
Patient Segmentation
Disease Risk & Burden
Risk of disease by the segmentation
Factors driving growth in a specific patient population

1. Key Insights
2. Disease Background and Overview: Herpes Simplex Virus (HSV)
2.1. Introduction
2.2. Stages of Herpes infection
2.3. Clinical manifestations
2.4. Risk Factors
2.5. Disease Causes
2.6. HSV-Symptoms
2.7. Pathogenesis
2.8. HSV Diagnosis
3. Epidemiology and Patient Population
4. Key Findings
4.1. Disease Definition
4.2. Population and Forecast Parameters
4.3. 7MM Prevalent Population of Herpes Simplex Virus (HSV)
4.4. 7MM Type-Specific Prevalent Population of Herpes Simplex Virus (HSV)
5. Country Wise-Epidemiology of Herpes Simplex Virus (HSV)
5.1. United States
5.1.1. Prevalent Population of HSV in the United States
5.1.2. Type-Specific HSV Prevalence in the United States
5.1.3. Diagnosed Cases of HSV in the United States
5.2. Germany
5.2.1. Prevalent Population of HSV in Germany
5.2.2. Type-Specific HSV Prevalence in Germany
5.2.3. Diagnosed Cases of HSV in Germany
5.3. France
5.3.1. Prevalent Population of HSV in France
5.3.2. Type-Specific HSV Prevalence in France
5.3.3. Diagnosed Cases of HSV in France
5.4. Italy
5.4.1. Prevalent Population of HSV in Italy
5.4.2. Type Specific HSV prevalence in Italy
5.4.3. Diagnosed cases of HSV in Italy
5.5. Spain
5.5.1. Prevalent Population of HSV in Spain
5.5.2. Type Specific HSV prevalence in Spain
5.5.3. Diagnosed cases of HSV in Spain
5.6. United Kingdom
5.6.1. Prevalent cases of HSV in the UK
5.6.2. Type Specific HSV prevalence in the UK
5.6.3. Diagnosed cases of HSV in the UK
5.7. Japan
5.7.1. Prevalent cases of HSV in Japan
5.7.2. Type Specific HSV prevalence in Japan
5.7.3. Diagnosed cases of HSV in Japan
6. Market Drivers of HSV
7. Market Barriers of HSV
8. Appendix
9. Report Methodology
9.1. Sources Used
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight

List Of Tables

Table 1: Prevalent Population of HSV in the 7MM (2016-2028)
Table 2: 7MM Type-Specific Prevalent Population of HSV (2016-2028)
Table 3: Prevalent Population of HSV in the United States (2016-2028)
Table 4: Type-Specific HSV Prevalence in the United States (2016-2028)
Table 5: Diagnosed Cases of HSV in the United States (2016-2028)
Table 6: Prevalent Population of HSV in Germany (2016-2028)
Table 7: Type-Specific HSV Prevalence in Germany (2016-2028)
Table 8: Diagnosed Cases of HSV in Germany (2016-2028)
Table 9: Prevalent Population of HSV in France (2016-2028)
Table 10: Type-Specific HSV Prevalence in France (2016-2028)
Table 11: Diagnosed Cases of HSV in France (2016-2028)
Table 12: Prevalent Population of HSV in Italy (2016-2028)
Table 13: Type-Specific HSV Prevalence in Italy (2016-2028)
Table 14: Diagnosed Cases of HSV in Italy (2016-2028)
Table 15: Prevalent Population of HSV in Spain (2016-2028)
Table 16: Type-Specific HSV Prevalence in Spain (2016-2028)
Table 17: Diagnosed Cases of HSV in Spain (2016-2028)
Table 18: Prevalent Population of HSV in the UK (2016-2028)
Table 19: Type-Specific HSV Prevalence in the UK (2016-2028)
Table 20: Diagnosed Cases of HSV in the UK (2016-2028)
Table 21: Prevalent Population of HSV in Japan (2016-2028)
Table 22: Type-Specific HSV Prevalence in Japan (2016-2028)
Table 23: Diagnosed Cases of HSV in Japan (2016-2028)

List Of Figures

Figure 1: Stages of Herpes infection
Figure 2: Clinical manifestations of Herpes infection
Figure 3: Risk factors associated with Herpes Simplex
Figure 4: Blisters
Figure 5: (a) Primary infection (b) Recurrent infection
Figure 6: Life Cycle of HSV infection
Figure 7: Establishment of primary infection
Figure 8: Prevalent Population of HSV in the 7MM (2016-2028)
Figure 9: 7MM Type-Specific Prevalent Population of HSV (2016-2028)
Figure 10: Prevalent Population of HSV in the United States (2016-2028)
Figure 11: Type-specific HSV Prevalence in the United States (2016-2028)
Figure 12: Diagnosed Cases of HSV in the United States (2016-2028)
Figure 13: Prevalent Population of HSV in Germany (2016-2028)
Figure 14: Type-specific HSV Prevalence in Germany (2016-2028)
Figure 15: Diagnosed Cases of HSV in Germany (2016-2028)
Figure 16: Prevalent Population of HSV in France (2016-2028)
Figure 17: Type-specific HSV Prevalence in France (2016-2028)
Figure 18: Diagnosed Cases of HSV in France (2016-2028)
Figure 19: Prevalent Population of HSV in Italy (2016-2028)
Figure 20: Type-specific HSV Prevalence in Italy (2016-2028)
Figure 21: Diagnosed Cases of HSV in Italy (2016-2028)
Figure 22: Prevalent Population of HSV in Spain (2016-2028)
Figure 23: Type-specific HSV Prevalence in Spain (2016-2028)
Figure 24: Diagnosed Cases of HSV in Spain (2016-2028)
Figure 25: Prevalent Population of HSV in the UK (2016-2028)
Figure 26: Type-specific HSV Prevalence in the UK (2016-2028)
Figure 27: Diagnosed Cases of HSV in the UK (2016-2028)
Figure 28: Prevalent Population of HSV in Japan (2016-2028)
Figure 29: Type-specific HSV Prevalence in Japan (2016-2028)
Figure 30: Diagnosed Cases of HSV in Japan (2016-2028)

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available